Comments to FDA: Developing Nicotine Replacement Therapy Drug Products Share page: Docket Number: FDA-2019-D-0297 CHPA welcomes the opportunity to comment on the draft guidance on indications for nicotine replacement therapies (NRT). Download Document Issues: OTC Medicines Rx-to-OTC Switch Other Issues Research Related Posts Regulation of OTC Medicines Press Releases and Statements CHPA Congratulates Dr. Doug Bierer as First Recipient of the William Cooley Regulatory & Scientific Affairs Career Achievement Award Sep 18, 2024 Press Releases and Statements Health In Hand Foundation Announces 2024 U.S. Self-Care Marketing Awards Finalists Sep 9, 2024